To verify whether PAFR could be a therapeutic target for the treatment of COPD, we observed the effects of rupatadine, a prescription dual antagonist for PAFR and histamine1 receptor (H1R), in mouse model of CS-induced COPD. This evidence concerns the gene HRH1 and chronic obstructive pulmonary disease.